Milestone Pharmaceuticals Inc (MIST) - Net Assets
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has net assets worth $20.50 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($87.75 Million) and total liabilities ($67.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MIST cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.50 Million |
| % of Total Assets | 23.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.81% |
| 10-Year Change | N/A |
| Growth Volatility | 32.23 |
Milestone Pharmaceuticals Inc - Net Assets Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore MIST current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual net assets of Milestone Pharmaceuticals Inc from 2017 to 2024. For live valuation and market cap data, see Milestone Pharmaceuticals Inc (MIST) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $13.15 Million | -21.61% |
| 2023-12-31 | $16.77 Million | -74.72% |
| 2022-12-31 | $66.35 Million | -41.08% |
| 2021-12-31 | $112.60 Million | -21.32% |
| 2020-12-31 | $143.12 Million | +24.54% |
| 2019-12-31 | $114.92 Million | +308.15% |
| 2018-12-31 | $-55.21 Million | -66.70% |
| 2017-12-31 | $-33.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Milestone Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33246000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $288.05 Million | 2190.98% |
| Other Comprehensive Income | $53.08 Million | 403.71% |
| Other Components | $39.57 Million | 300.97% |
| Total Equity | $13.15 Million | 100.00% |
Milestone Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EKOS
IS:EKOS
|
$155.03 Million |
|
Intai Technology
TWO:4163
|
$155.03 Million |
|
Pro-Dex Inc
NASDAQ:PDEX
|
$155.04 Million |
|
GPT Infraprojects Limited
NSE:GPTINFRA
|
$155.08 Million |
|
BingEx Ltd
NASDAQ:FLX
|
$154.95 Million |
|
Roularta
BR:ROU
|
$154.88 Million |
|
ABOV Semiconductor Co. Ltd
KQ:102120
|
$154.85 Million |
|
Southern Petrochemicals Industries Corporation Limited
NSE:SPIC
|
$154.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Milestone Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,771,000 to 13,147,000, a change of -3,624,000 (-21.6%).
- Net loss of 41,519,000 reduced equity.
- New share issuances of 27,258,000 increased equity.
- Other comprehensive income increased equity by 4,617,000.
- Other factors increased equity by 6,020,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.52 Million | -315.81% |
| Share Issuances | $27.26 Million | +207.33% |
| Other Comprehensive Income | $4.62 Million | +35.12% |
| Other Changes | $6.02 Million | +45.79% |
| Total Change | $- | -21.61% |
Book Value vs Market Value Analysis
This analysis compares Milestone Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.40 | $1.87 | x |
| 2018-12-31 | $-2.33 | $1.87 | x |
| 2019-12-31 | $7.28 | $1.87 | x |
| 2020-12-31 | $4.88 | $1.87 | x |
| 2021-12-31 | $2.69 | $1.87 | x |
| 2022-12-31 | $1.56 | $1.87 | x |
| 2023-12-31 | $0.39 | $1.87 | x |
| 2024-12-31 | $0.21 | $1.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Milestone Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -315.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.74x
- Recent ROE (-315.81%) is below the historical average (-109.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.77 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.66 Million |
| 2019 | -48.06% | 0.00% | 0.00x | 1.07x | $-66.72 Million |
| 2020 | -34.91% | -333.11% | 0.10x | 1.05x | $-64.28 Million |
| 2021 | -38.06% | -285.69% | 0.13x | 1.06x | $-54.11 Million |
| 2022 | -86.11% | -1142.68% | 0.07x | 1.12x | $-63.77 Million |
| 2023 | -355.88% | -5968.50% | 0.01x | 4.49x | $-61.36 Million |
| 2024 | -315.81% | 0.00% | 0.00x | 5.74x | $-42.83 Million |
Industry Comparison
This section compares Milestone Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Milestone Pharmaceuticals Inc (MIST) | $20.50 Million | 0.00% | 3.28x | $155.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more